-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It has only been less than a month since the opening of 2022, and the pharmaceutical industry has received many good news.
On the one hand, major listed pharmaceutical companies have released their 2021 performance forecasts one after another.
Overall, the performance is good, with about 80% of the company’s performance forecast; on the other hand, in the In the context of accelerated new drug approval and review, many innovative drugs have been approved for clinical trials
.
According to statistics, as of January 20, 74 listed companies in the pharmaceutical and biological industry have released 2021 performance forecasts or performance reports, of which 80% are pre-happy
.
Wohua Pharmaceutical is the first pharmaceutical company to disclose the express report, and its performance has been stable and slightly decreased
.
Among the pharmaceutical companies with good results, those with a net profit increase of more than 100% include Oriental Bio, Yirui Bio, Jiu’an Medical, Hualan, Yan’an Bikang, Kaipu Bio, Mingde Bio, Zhongsheng Pharmaceutical, Hai Chen Pharmaceutical, Medicilon, Kangenbei, etc.
, Rejing Bio is expected to increase its net profit by 1684.
65% to 1996.
97% year-on-year in 2021, and the data is very eye-catching
.
Judging from the above-mentioned companies with promising performance, their industries mainly focus on high-prosperity sub-tracks such as CXO, in vitro diagnostics, and APIs
.
Among them, in the CXO industry, affected by the strong demand for orders in 2021, the performance of CXO companies continued to maintain strong growth.
For example, Medicilon expects that the net profit for 2021 will be 278 million to 291 million yuan, an increase of 115% to 125%.
; WuXi AppTec's net profit in 2021 is expected to increase by about 70%
.
From the perspective of the industry background, with the transfer of the global industrial chain, coupled with the domestic engineer bonus, cost advantages, the acceleration of drug review reform and the upgrade of drug innovation, the domestic CXO industry is relatively prosperous
.
In addition, in the field of in vitro diagnostics, Rejing Bio, Mingde Bio, Oriental Bio, and Kaipu Bio have continued their high growth
.
For the substantial increase in annual performance, Rejing Bio, which has the highest performance growth rate, said that it was mainly due to two factors
.
On the one hand, the comparison base in 2020 is low; on the other hand, the company's foreign trade orders have grown explosively in the first half of the year.
It is reported that in the second half of the year, the overseas market's demand for the company's antigen detection reagents has grown significantly
.
Several innovative drugs were approved for clinical trials From January 14th to January 20th, there were good news about the clinical approval of a number of blockbuster innovative drug projects in China, which deserves continuous attention in the industry
.
For example, on January 18, CDE's public information showed that the clinical trial application of TSN084 tablets of Taili Bio was approved by the Food and Drug Administration for the treatment of advanced or metastatic malignant tumors
.
TSN084 is a first-in-class multi-kinase inhibitor targeting CDK8/19 and several other kinases closely related to tumor proliferation and immune escape
.
The U.
S.
clinical application for the product was approved by the FDA on October 17, 2021, for the treatment of solid tumors
.
Recently, Osaikang announced that its wholly-owned subsidiary ASKG712 injection has been approved for clinical trials
.
Application indication: neovascular age-related macular degeneration (nAMD)
.
ASKG712 is a bispecific antibody independently developed by the subsidiary that targets both VEGF and ANG2
.
While blocking the VEGF/VEGFR signaling pathway and controlling the formation of new blood vessels, it can effectively inhibit ANG-2 signaling to improve vascular stability and reduce retinal inflammation
.
At present, there is no bispecific antibody with the same target on the market
.
In addition, Huadong Medicine recently announced that on January 18, 2022, the company's holding subsidiary received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration.
The Phase I clinical trial application was approved to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of the humanized Claudin18.
2 monoclonal antibody-DR30303 in the treatment of advanced solid tumors
.
At present, there is no anti-Claudin18.
2 drug on the market in the world
.
On the one hand, major listed pharmaceutical companies have released their 2021 performance forecasts one after another.
Overall, the performance is good, with about 80% of the company’s performance forecast; on the other hand, in the In the context of accelerated new drug approval and review, many innovative drugs have been approved for clinical trials
.
According to statistics, as of January 20, 74 listed companies in the pharmaceutical and biological industry have released 2021 performance forecasts or performance reports, of which 80% are pre-happy
.
Wohua Pharmaceutical is the first pharmaceutical company to disclose the express report, and its performance has been stable and slightly decreased
.
Among the pharmaceutical companies with good results, those with a net profit increase of more than 100% include Oriental Bio, Yirui Bio, Jiu’an Medical, Hualan, Yan’an Bikang, Kaipu Bio, Mingde Bio, Zhongsheng Pharmaceutical, Hai Chen Pharmaceutical, Medicilon, Kangenbei, etc.
, Rejing Bio is expected to increase its net profit by 1684.
65% to 1996.
97% year-on-year in 2021, and the data is very eye-catching
.
Judging from the above-mentioned companies with promising performance, their industries mainly focus on high-prosperity sub-tracks such as CXO, in vitro diagnostics, and APIs
.
Among them, in the CXO industry, affected by the strong demand for orders in 2021, the performance of CXO companies continued to maintain strong growth.
For example, Medicilon expects that the net profit for 2021 will be 278 million to 291 million yuan, an increase of 115% to 125%.
; WuXi AppTec's net profit in 2021 is expected to increase by about 70%
.
From the perspective of the industry background, with the transfer of the global industrial chain, coupled with the domestic engineer bonus, cost advantages, the acceleration of drug review reform and the upgrade of drug innovation, the domestic CXO industry is relatively prosperous
.
In addition, in the field of in vitro diagnostics, Rejing Bio, Mingde Bio, Oriental Bio, and Kaipu Bio have continued their high growth
.
For the substantial increase in annual performance, Rejing Bio, which has the highest performance growth rate, said that it was mainly due to two factors
.
On the one hand, the comparison base in 2020 is low; on the other hand, the company's foreign trade orders have grown explosively in the first half of the year.
It is reported that in the second half of the year, the overseas market's demand for the company's antigen detection reagents has grown significantly
.
Several innovative drugs were approved for clinical trials From January 14th to January 20th, there were good news about the clinical approval of a number of blockbuster innovative drug projects in China, which deserves continuous attention in the industry
.
For example, on January 18, CDE's public information showed that the clinical trial application of TSN084 tablets of Taili Bio was approved by the Food and Drug Administration for the treatment of advanced or metastatic malignant tumors
.
TSN084 is a first-in-class multi-kinase inhibitor targeting CDK8/19 and several other kinases closely related to tumor proliferation and immune escape
.
The U.
S.
clinical application for the product was approved by the FDA on October 17, 2021, for the treatment of solid tumors
.
Recently, Osaikang announced that its wholly-owned subsidiary ASKG712 injection has been approved for clinical trials
.
Application indication: neovascular age-related macular degeneration (nAMD)
.
ASKG712 is a bispecific antibody independently developed by the subsidiary that targets both VEGF and ANG2
.
While blocking the VEGF/VEGFR signaling pathway and controlling the formation of new blood vessels, it can effectively inhibit ANG-2 signaling to improve vascular stability and reduce retinal inflammation
.
At present, there is no bispecific antibody with the same target on the market
.
In addition, Huadong Medicine recently announced that on January 18, 2022, the company's holding subsidiary received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration.
The Phase I clinical trial application was approved to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of the humanized Claudin18.
2 monoclonal antibody-DR30303 in the treatment of advanced solid tumors
.
At present, there is no anti-Claudin18.
2 drug on the market in the world
.
